PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 30195172-10 2019 RESULTS: TT and FT levels were positively correlated with GABA+ levels in the PCC. Tegafur 16-18 crystallin gamma D Homo sapiens 78-81 30524750-1 2018 Background: S-1 (a combination of tegafur, gimeracil, and oteracil) is used to treat various cancers. Tegafur 34-41 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 29931401-0 2018 Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1. Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 123-126 29721725-7 2018 The distant metastasis rate in the tegafur-uracil group was significantly lower than the control group, indicating that administration of tegafur-uracil after curative surgical treatment and concurrent chemoradiotherapy prevented distant metastasis and improved the OS, DFS, and DSS rate. Tegafur 35-49 peripheral myelin protein 22 Homo sapiens 279-282 29721725-7 2018 The distant metastasis rate in the tegafur-uracil group was significantly lower than the control group, indicating that administration of tegafur-uracil after curative surgical treatment and concurrent chemoradiotherapy prevented distant metastasis and improved the OS, DFS, and DSS rate. Tegafur 138-152 peripheral myelin protein 22 Homo sapiens 279-282 29721725-8 2018 CONCLUSIONS: The result of tegafur-uracil treatment in patients with advanced oral cancer showed significant improvement in the 5-year OS, DFS, and DSS rate, while also showing a decreased distant metastasis rate. Tegafur 27-34 peripheral myelin protein 22 Homo sapiens 148-151 29931401-1 2018 PURPOSE: To establish a method for the measurement of 5-fluorouracil (5-FU), and tegafur (FT) in tear samples from patients treated with oral fluoropyrimidine anticancer agent S-1. Tegafur 81-88 proteasome 26S subunit, non-ATPase 1 Homo sapiens 176-179 29931401-1 2018 PURPOSE: To establish a method for the measurement of 5-fluorouracil (5-FU), and tegafur (FT) in tear samples from patients treated with oral fluoropyrimidine anticancer agent S-1. Tegafur 90-92 proteasome 26S subunit, non-ATPase 1 Homo sapiens 176-179 29931401-10 2018 The mean concentrations of 5-FU and FT in tears during S-1 treatment were 0.17 +- 0.11 and 1.94 +- 0.71 mug/mL, respectively. Tegafur 36-38 proteasome 26S subunit, non-ATPase 1 Homo sapiens 55-58 29191594-1 2017 INTRODUCTION: S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium. Tegafur 67-74 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 29996281-2 2018 Tegafur is the major active prodrug, which is metabolized to 5-Fu by cytochrome P4502A6 (CYP2A6). Tegafur 0-7 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 89-95 29445512-2 2018 The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). Tegafur 115-122 proteasome 26S subunit, non-ATPase 1 Homo sapiens 152-155 28698442-1 2017 S-1 is an oral antineoplastic agent containing tegafur, gimeracil, and oteracil potassium. Tegafur 47-54 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 28835573-10 2017 Among the 168 patients, 59 patients were treated with tegafur-uracil (UFT), a DPD-inhibitory fluoropyrimidine, and the UFT-treated patients with high TS and high DPD levels showed worst prognosis. Tegafur 54-68 thymidylate synthetase Homo sapiens 150-152 28835573-10 2017 Among the 168 patients, 59 patients were treated with tegafur-uracil (UFT), a DPD-inhibitory fluoropyrimidine, and the UFT-treated patients with high TS and high DPD levels showed worst prognosis. Tegafur 54-68 dihydropyrimidine dehydrogenase Homo sapiens 162-165 28417167-0 2017 Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. Tegafur 124-138 gamma-glutamyl hydrolase Homo sapiens 26-50 25874010-1 2015 PURPOSE: The aim of this study was to clarify the risk factors for discontinuing tegafur/gimeracil/oteracil potassium (S-1) adjuvant chemotherapy following gastrectomy in patients with gastric cancer. Tegafur 81-88 proteasome 26S subunit, non-ATPase 1 Homo sapiens 119-122 28347333-10 2017 The UMPS 638 CC genotype might be a candidate biomarker predicting toxicity in patients receiving tegafur-uracil/leucovorin-based preoperative chemoradiation for locally advanced rectal cancer. Tegafur 98-105 uridine monophosphate synthetase Homo sapiens 4-8 28449472-3 2017 Patients received S-1 (tegafur/gimeracil/oteracil) and cisplatin at doses of 70 mg/m2/day for two weeks and 75 mg/m2 on day 1, respectively, every 3 weeks. Tegafur 23-30 proteasome 26S subunit, non-ATPase 1 Homo sapiens 18-21 27966431-1 2017 INTRODUCTION: The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. Tegafur 57-64 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 28496035-1 2017 S-1 is an anticancer agent that consists of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:0.4:1. Tegafur 44-51 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 27980246-1 2017 S-1 is a new oral fluoropyrimidine formulation that comprises tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. Tegafur 62-69 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 27919974-2 2016 We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. Tegafur 44-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-148 27919974-2 2016 We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. Tegafur 60-63 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-148 27822036-3 2016 Recently, we have reported that metronomic S-1, orally available tegafur formulation, dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome without increasing the toxicity in animal model. Tegafur 65-72 proteasome 26S subunit, non-ATPase 1 Homo sapiens 43-46 27749261-6 2016 In the fully adjusted model (n=414), the third quartile of the O*NET noise exposure was associated with lower TT and FT, which reached statistically significant decrease of -58.32 ng dL-1 (95 % CI: -111.22, -5.42) and -1.58 ng dL-1 (95 % CI: -2.98, -0.18), respectively. Tegafur 117-119 l(1)L1 Drosophila melanogaster 183-187 27749261-6 2016 In the fully adjusted model (n=414), the third quartile of the O*NET noise exposure was associated with lower TT and FT, which reached statistically significant decrease of -58.32 ng dL-1 (95 % CI: -111.22, -5.42) and -1.58 ng dL-1 (95 % CI: -2.98, -0.18), respectively. Tegafur 117-119 l(1)L1 Drosophila melanogaster 227-231 27089049-13 2016 Extended RAS (KRAS/NRAS) mutations are proposed as predictive indicators with respect to the efficacy of adjuvant UFT chemotherapy in patients with resected stage III colorectal cancer. Tegafur 114-117 KRAS proto-oncogene, GTPase Homo sapiens 14-18 27089049-13 2016 Extended RAS (KRAS/NRAS) mutations are proposed as predictive indicators with respect to the efficacy of adjuvant UFT chemotherapy in patients with resected stage III colorectal cancer. Tegafur 114-117 NRAS proto-oncogene, GTPase Homo sapiens 19-23 26651493-1 2016 DPD is the rate-limiting enzyme involved in the metabolism of 5-fluorouracil and its prodrugs, capecitabine and tegafur. Tegafur 112-119 dihydropyrimidine dehydrogenase Homo sapiens 0-3 25652909-3 2015 S-1 is a tegafur-based oral 5-FU prodrug which has been widely introduced in Japan and other countries. Tegafur 9-16 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 25810324-1 2015 S-1 is an oral 5-fluorouracil agent containing tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 47-54 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 28159957-1 2017 Background: S-1 is a combination of tegafur [metabolized to 5-fluorouracil (5-FU)] with the modulators gimeracil (5-chloro-2,4-dihydroxypyridine) and oteracil potassium. Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 233-249 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 251-257 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 uridine monophosphate synthetase Homo sapiens 260-292 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 uridine monophosphate synthetase Homo sapiens 294-298 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 ATP binding cassette subfamily B member 1 Homo sapiens 305-328 28347333-1 2017 BACKGROUND: This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 (CYP2A6), uridine monophosphate synthetase (UMPS), and ATP-binding cassette B1 (ABCB1) on clinical outcome. Tegafur 77-91 ATP binding cassette subfamily B member 1 Homo sapiens 330-335 28103584-4 2017 TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g. Tegafur 92-99 ADAM metallopeptidase domain 17 Homo sapiens 0-4 26715117-1 2017 BACKGROUND: Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). Tegafur 47-54 proteasome 26S subunit, non-ATPase 1 Homo sapiens 34-37 26715117-1 2017 BACKGROUND: Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). Tegafur 47-54 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 98-117 26715117-1 2017 BACKGROUND: Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). Tegafur 47-54 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 119-125 27919974-0 2016 A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy. Tegafur 45-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 97-101 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 12-26 thymidylate synthetase Homo sapiens 70-90 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 12-26 thymidylate synthetase Homo sapiens 92-94 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 28-31 thymidylate synthetase Homo sapiens 70-90 25922722-1 2015 BACKGROUND: Tegafur-uracil (UFT) is an anticancer agent that inhibits thymidylate synthase (TS). Tegafur 28-31 thymidylate synthetase Homo sapiens 92-94 25550184-4 2015 Here we assumed that DCN silencing cells increase chemosusceptibility to S-1, consisted of tegafur, prodrug of 5-fluorouracil. Tegafur 91-98 decorin Homo sapiens 21-24 23821376-0 2014 Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Tegafur 150-153 KRAS proto-oncogene, GTPase Homo sapiens 8-12 25460024-8 2015 In addition, administration of FTS decreased pancreatic levels of CXC chemokines as well as circulating levels of interleukin-6 and high-mobility group box 1 in animals exposed to taurocholate. Tegafur 31-34 interleukin 6 Mus musculus 114-127 25460024-8 2015 In addition, administration of FTS decreased pancreatic levels of CXC chemokines as well as circulating levels of interleukin-6 and high-mobility group box 1 in animals exposed to taurocholate. Tegafur 31-34 high mobility group box 1 Mus musculus 132-157 25109221-1 2014 INTRODUCTION: S-1 is an oral fluoropyrimidine derivative, including three pharmacological compounds: tegafur, gimeracil and oteracil, in a molar ratio of 1: 0.4: 1. Tegafur 101-108 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 25032886-1 2014 INTRODUCTION: S-1 is an oral fluoropyrimidine that consists of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate. Tegafur 63-70 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 25596051-11 2014 The CBR was significantly higher for patients with no visceral metastasis (p=0.032), TS-1 used as third-line treatment or earlier (p=0.019), negative HER2 status (p= 0.045), no history of CAP therapy (p=0.006), and no history of tegafur-uracil/doxifluridine therapy (p=0.031). Tegafur 229-243 cannabinoid receptor 1 Homo sapiens 4-7 25550798-15 2014 Celecoxib and celecoxib in combination with tegafur/gimeracil/oteracil potassium possibly by reducing the expression of COX-2, in turn down-regulating the expression of VEGF-C, resulted in the inhibition of lymphangiogenesis. Tegafur 44-51 prostaglandin-endoperoxide synthase 2 Mus musculus 120-125 25550798-15 2014 Celecoxib and celecoxib in combination with tegafur/gimeracil/oteracil potassium possibly by reducing the expression of COX-2, in turn down-regulating the expression of VEGF-C, resulted in the inhibition of lymphangiogenesis. Tegafur 44-51 vascular endothelial growth factor C Mus musculus 169-175 25408647-4 2014 These findings suggest that intra-arterial administration of peplomycin with tegafur is one of the optimal therapies for the treatment of SCC developing on the ear. Tegafur 77-84 serpin family B member 3 Homo sapiens 138-141 25002745-0 2014 Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity. Tegafur 69-76 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 10-16 23821376-0 2014 Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Tegafur 150-153 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 20-24 23821376-0 2014 Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Tegafur 150-153 tumor protein p53 Homo sapiens 29-33 24743359-1 2014 Japanese clinical trials of a tegafur/uracil(UFT)-based postoperative chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil(CMF)treatment have shown that UFT is not inferior to CMF for the treatment of hormone receptor-positive breast cancer patients. Tegafur 45-48 nuclear receptor subfamily 4 group A member 1 Homo sapiens 232-248 23998404-1 2013 BACKGROUND: Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced non-small cell lung cancer with acceptable toxicity. Tegafur 62-69 proteasome 26S subunit, non-ATPase 1 Homo sapiens 47-50 23982118-8 2013 The exploratory pharmacokinetic/pharmacogenetic study showed that CYP2A6 variants (*4, *7, *9) are associated with a lower metabolic ratio of S-1 (exposure ratio of 5-fluorouracil to tegafur). Tegafur 183-190 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 66-72 23982118-8 2013 The exploratory pharmacokinetic/pharmacogenetic study showed that CYP2A6 variants (*4, *7, *9) are associated with a lower metabolic ratio of S-1 (exposure ratio of 5-fluorouracil to tegafur). Tegafur 183-190 proteasome 26S subunit, non-ATPase 1 Homo sapiens 142-145 23739924-2 2014 Gamma-butyrolactone (GBL) is a metabolite of tegafur that is known to suppress vascular endothelial growth factor (VEGF)-mediated angiogenic activity. Tegafur 45-52 vascular endothelial growth factor A Homo sapiens 79-113 23739924-2 2014 Gamma-butyrolactone (GBL) is a metabolite of tegafur that is known to suppress vascular endothelial growth factor (VEGF)-mediated angiogenic activity. Tegafur 45-52 vascular endothelial growth factor A Homo sapiens 115-119 24649225-0 2013 Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy. Tegafur 166-174 solute carrier family 22 member 7 Homo sapiens 32-59 23898115-0 2013 Reduction in gamma-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer. Tegafur 91-98 gamma-glutamyl hydrolase Homo sapiens 13-37 23585145-1 2013 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur). Tegafur 145-152 dihydropyrimidine dehydrogenase Homo sapiens 0-31 23585145-1 2013 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur). Tegafur 145-152 dihydropyrimidine dehydrogenase Homo sapiens 33-36 23180349-3 2013 METHODS: Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX). Tegafur 212-215 BCL2 associated X, apoptosis regulator Homo sapiens 9-12 23180349-3 2013 METHODS: Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX). Tegafur 256-259 BCL2 associated X, apoptosis regulator Homo sapiens 9-12 25505563-0 2013 Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes. Tegafur 66-73 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 26-41 25505563-1 2013 Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes. Tegafur 0-7 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 139-154 25505563-1 2013 Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes. Tegafur 0-7 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 156-159 25505563-1 2013 Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes. Tegafur 9-11 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 139-154 25505563-1 2013 Tegafur (FT) is a prodrug of 5-fluorouracil (5-FU) used in cancer chemotherapy, and the bioactivation of FT to 5-FU is mainly catalyzed by cytochrome P450 (CYP) in hepatic microsomes. Tegafur 9-11 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 156-159 23482788-8 2013 For patients with high expression of ERCC1 and tubulin, uracil-tegafur, pemetrexed, and gemcitabine may be the alternative agents for personalized chemotherapy. Tegafur 63-70 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 23710321-2 2013 Here, we report a case of advanced metastatic CBD cancer successfully treated by chemotherapy with gemcitabine combined with S-1 (tegafur+gimeracil+oteracil). Tegafur 130-137 proteasome 26S subunit, non-ATPase 1 Homo sapiens 125-128 23267878-3 2012 We conducted a clinical trial of vaccines against colorectal cancer specific peptides(RNF43 and TOMM34) with tegafur-uracil/Leucovorin( UFT/LV) for the treatment of advanced or recurrent colorectal cancer. Tegafur 109-123 translocase of outer mitochondrial membrane 34 Homo sapiens 96-102 23221058-0 2012 [A case of successful treatment of granulocyte colony-stimulating factor producing hepatocellular carcinoma accompanying type B hepatitis with tegafur-uracil]. Tegafur 143-157 colony stimulating factor 3 Homo sapiens 35-72 22860709-2 2012 S-1 , a fourth-generation oral fluoropyrimidine that combines tegafur and two biochemical modulators: gimeracil and oteracil potassium, is now attracting considerable interest. Tegafur 62-69 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 23289150-1 2012 The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer after single and multiple oral administration. Tegafur 65-72 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 23289150-7 2012 After six days oral administration, the average steady state plasma concentrations (Cav) of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil were (2,425 +/- 1,172), (73.88 +/- 18.88), (162.6 +/- 70.8), (36.89 +/- 29.35) and (435.3 +/- 141.0) ng x mL(-1), respectively, and the degree of fluctuation (DF) were (1.0 +/- 0.2), (2.5 +/- 0.4), (3.1 +/- 0.8), (2.4 +/- 0.8) and (1.5 +/- 0.3), respectively. Tegafur 92-99 caveolin 2 Homo sapiens 84-87 22876791-1 2012 BACKGROUND: TS-1 is an oral anticancer drug containing a 5-fluorouracil derivative (Tegafur) that is widely used in Japan for the treatment of cancer, especially gastrointestinal tumors. Tegafur 84-91 Trichinella spiralis resistance 1 Mus musculus 12-16 21521021-0 2011 Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Tegafur 91-98 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 24-30 22251528-0 2012 Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer. Tegafur 59-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 48-51 21675835-8 2011 One oral fluoropyrimidine, S-1, is novel as it combines tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate. Tegafur 56-63 proteasome 26S subunit, non-ATPase 1 Homo sapiens 27-30 22322240-1 2012 S-1 is an oral antitumor agent that contains tegafur, which is converted to fluorouracil (5-FU) in the human body. Tegafur 45-52 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 22322240-2 2012 Cytochrome P450 2A6 (CYP2A6) is the principal enzyme responsible for bioconversion of tegafur to 5-FU. Tegafur 98-105 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 0-19 22322240-2 2012 Cytochrome P450 2A6 (CYP2A6) is the principal enzyme responsible for bioconversion of tegafur to 5-FU. Tegafur 98-105 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 21-27 22241359-1 2012 The S-1(tegafur/gimeracil/oteracil potassium)granule was developed to meet the needs of patients with cancer. Tegafur 8-15 proteasome 26S subunit, non-ATPase 1 Homo sapiens 4-7 22011696-1 2011 OBJECTIVE: We report three cases of elevated prothrombin time-international normalized ratios (PT-INR) following the initiation of coadministration of warfarin and S-1, a preparation containing tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo). Tegafur 203-205 cadherin 3 Homo sapiens 219-223 20714726-1 2011 PURPOSE: To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. Tegafur 97-104 proteasome 26S subunit, non-ATPase 1 Homo sapiens 74-77 20714726-1 2011 PURPOSE: To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. Tegafur 106-108 proteasome 26S subunit, non-ATPase 1 Homo sapiens 74-77 21521021-1 2011 AIM: Tegafur is primarily converted to 5-fluorouracil (5-FU) by CYP2A6 in the human liver to exert its antitumor effect. Tegafur 5-12 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 64-70 21487460-2 2011 We describe the case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer. Tegafur 120-127 proteasome 26S subunit, non-ATPase 1 Homo sapiens 115-118 20463005-5 2010 Succinaldehyde (SA) and 4-hydroxybutanal (4-OH-BTL) were produced as the metabolites because of the cleavage of the furan ring of FT during its conversion to 5-FU in cDNA-expressed CYP2A6 and purified TPase, respectively; however, GBL/GHB was hardly detected in cDNA-expressed CYP2A6 and purified TPase. Tegafur 130-132 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 181-187 21378348-14 2011 Thus, the DPD inhibitory action of CDHP contributes to a decrease in 5-FU catabolism and to significantly higher blood levels of 5-FU compared to FT alone. Tegafur 146-148 dihydropyrimidine dehydrogenase Homo sapiens 10-13 21378348-14 2011 Thus, the DPD inhibitory action of CDHP contributes to a decrease in 5-FU catabolism and to significantly higher blood levels of 5-FU compared to FT alone. Tegafur 146-148 cadherin 3 Homo sapiens 35-39 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 257-264 thymidylate synthetase Homo sapiens 84-104 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 257-264 uridine monophosphate synthetase Homo sapiens 114-147 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 257-264 uridine monophosphate synthetase Homo sapiens 149-153 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 266-269 thymidylate synthetase Homo sapiens 84-104 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 266-269 uridine monophosphate synthetase Homo sapiens 114-147 20647221-1 2011 BACKGROUND: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV). Tegafur 266-269 uridine monophosphate synthetase Homo sapiens 149-153 20647221-8 2011 CONCLUSIONS: OPRT polymorphism predicts toxicity, especially grade 3 or greater diarrhea to oral UFT + LV adjuvant chemotherapy, whereas TS does not, in our study cohort. Tegafur 97-100 uridine monophosphate synthetase Homo sapiens 13-17 22162925-1 2011 S-1 is a combination of three pharmacological compounds, namely tegafur, gimeracil, and oteracil potassium. Tegafur 64-71 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 22870097-0 2010 Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Tegafur 68-82 thymidylate synthetase Homo sapiens 156-176 20948275-0 2010 [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2]. Tegafur 1-15 interleukin 2 Homo sapiens 120-133 20948275-6 2010 Therefore, the treatment was switched to natural human IFNa with tegafur-uracil at 300 mg per day since February 2009. Tegafur 65-79 interferon alpha 2 Homo sapiens 55-59 20463005-5 2010 Succinaldehyde (SA) and 4-hydroxybutanal (4-OH-BTL) were produced as the metabolites because of the cleavage of the furan ring of FT during its conversion to 5-FU in cDNA-expressed CYP2A6 and purified TPase, respectively; however, GBL/GHB was hardly detected in cDNA-expressed CYP2A6 and purified TPase. Tegafur 130-132 MTOR associated protein, LST8 homolog Homo sapiens 231-238 20463005-5 2010 Succinaldehyde (SA) and 4-hydroxybutanal (4-OH-BTL) were produced as the metabolites because of the cleavage of the furan ring of FT during its conversion to 5-FU in cDNA-expressed CYP2A6 and purified TPase, respectively; however, GBL/GHB was hardly detected in cDNA-expressed CYP2A6 and purified TPase. Tegafur 130-132 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 277-283 20078321-3 2010 We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction. Tegafur 111-125 serpin family A member 5 Homo sapiens 68-71 19921195-1 2010 PURPOSE: S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. Tegafur 51-58 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 19921195-1 2010 PURPOSE: S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. Tegafur 60-62 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 22966328-3 2010 An oral combined fluoropyrimidine drug, S-1 (tegafur, gimeracil and oteracil), has recently been introduced alone or in combination with gemcitabine for BDC. Tegafur 45-52 proteasome 26S subunit, non-ATPase 1 Homo sapiens 40-43 20414030-0 2010 [Successful management with S-1 of recurrent gastric cancer after adjuvant chemotherapy with paclitaxel/UFT]. Tegafur 104-107 proteasome 26S subunit, non-ATPase 1 Homo sapiens 28-31 20559897-1 2010 BACKGROUND: Irinotecan and S-1, an oral fluoropyrimidine composed of tegafur, gimeracil, and oteracil potassium, have demonstrated antitumor activity against advanced gastric cancer. Tegafur 69-76 proteasome 26S subunit, non-ATPase 1 Homo sapiens 27-30 20424000-4 2010 We used 5-fluorouracil (5FU) instead of S-1 for in vitro experiments, given that tegafur, a component of S-1, is metabolized to 5FU in the liver. Tegafur 81-88 proteasome 26S subunit, non-ATPase 1 Homo sapiens 105-108 20078321-9 2010 CONCLUSIONS: This is probably the first report of PCI with PBG related to intestinal toxicity during cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy in a patient with advanced rectal carcinoma, followed by delayed small bowel perforation. Tegafur 125-139 serpin family A member 5 Homo sapiens 50-53 18383902-1 2008 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo), based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 49-56 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 189-197 dihydropyrimidine dehydrogenase Homo sapiens 33-36 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 199-202 dihydropyrimidine dehydrogenase Homo sapiens 0-31 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 199-202 dihydropyrimidine dehydrogenase Homo sapiens 33-36 19724848-1 2009 S-1, an oral fluorouracil antitumor drug, is composed of three agents: tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo). Tegafur 71-78 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 19724848-1 2009 S-1, an oral fluorouracil antitumor drug, is composed of three agents: tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo). Tegafur 80-82 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 19632949-1 2009 S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Tegafur 127-134 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 18212800-2 2008 Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6. Tegafur 0-7 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 140-146 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 189-197 dihydropyrimidine dehydrogenase Homo sapiens 0-31 20037296-5 2009 Among the patients who were given PSK, the frequency of concomitant use of UFT alone was higher in Stage III a patients, while the rate of concomitant use of fluoropyrimidines and Leucovorin was higher in Stage III b patients (p<0.01). Tegafur 75-78 TAO kinase 2 Homo sapiens 34-37 19604090-1 2009 AIMS: S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. Tegafur 46-53 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 102-108 19243284-2 2009 S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or CDHP), a competitive inhibitor of dihydropyrimidine dehydrogenase and oteracil potassium which inhibits phosphorylation of 5-FU in the gastrointestinal tract decreasing serious gastrointestinal toxicities,including nausea, vomiting, stomatitis and diarrhea. Tegafur 16-23 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 19015148-1 2009 BACKGROUND: A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas. Tegafur 95-98 dihydropyrimidine dehydrogenase Homo sapiens 205-236 19015148-1 2009 BACKGROUND: A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas. Tegafur 95-98 dihydropyrimidine dehydrogenase Homo sapiens 238-241 19052037-5 2009 S-1 is an oral anticancer agent containing two biochemical modulators for 5-FU and tegafur (FT), a metabolically activated prodrug of 5-FU. Tegafur 83-90 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 18383902-1 2008 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo), based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 58-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 17549346-3 2007 The present study was designed to assess the association between the activity of OPRT in the tumor, and the clinicopathological status and prognosis of human resectable pancreatic cancer, especially regarding its relevance to the efficacy of adjuvant chemotherapy with uracil and tegafur (UFT), cyclophosphamide (CPA) and/or gemcitabine (GEM). Tegafur 280-287 uridine monophosphate synthetase Homo sapiens 81-85 17764620-0 2007 Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Tegafur 35-42 TAO kinase 2 Mus musculus 129-132 17764620-0 2007 Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Tegafur 51-54 TAO kinase 2 Mus musculus 129-132 17695427-0 2007 Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Tegafur 160-163 thymidylate synthetase Homo sapiens 20-40 17695427-0 2007 Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Tegafur 160-163 dihydropyrimidine dehydrogenase Homo sapiens 45-76 17761979-4 2007 PATIENTS AND METHODS: The EGFR mutational status of 187 patients with resected lung adenocarcinomas was determined using a polymerase chain reaction-based assay for EGFR exons 19 and 21; the results were then correlated with the effect of adjuvant uracil-tegafur chemotherapy on survival. Tegafur 255-262 epidermal growth factor receptor Homo sapiens 26-30 17549346-3 2007 The present study was designed to assess the association between the activity of OPRT in the tumor, and the clinicopathological status and prognosis of human resectable pancreatic cancer, especially regarding its relevance to the efficacy of adjuvant chemotherapy with uracil and tegafur (UFT), cyclophosphamide (CPA) and/or gemcitabine (GEM). Tegafur 289-292 uridine monophosphate synthetase Homo sapiens 81-85 17549346-8 2007 In the OPRT (+) group, the survival rate of the patients, who received adjuvant chemotherapy (ACT) with UFT, CPA or GEM, was significantly higher than that of the patients without ACT; however, in the OPRT (-) group, there was no difference in the survival between the ACT (+) and (-) groups. Tegafur 104-107 uridine monophosphate synthetase Homo sapiens 7-11 17922560-9 2007 The bid : tid AUC(24) ratio (90% CI) was 1.8 (1.55, 2.10) with fluorouracil, 2.0 (1.59, 2.57) with uracil and 1.2 (1.02, 1.36) with tegafur, indicating that the bid and tid schedules were not bioequivalent. Tegafur 132-139 BH3 interacting domain death agonist Homo sapiens 4-7 17603216-1 2007 BACKGROUND: TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. Tegafur 49-56 dihydropyrimidine dehydrogenase Homo sapiens 132-163 17603216-1 2007 BACKGROUND: TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. Tegafur 49-56 dihydropyrimidine dehydrogenase Homo sapiens 165-168 16786333-1 2007 PURPOSE: S-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. Tegafur 60-67 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 17603216-2 2007 UFT is a combination preparation of tegafur with uracil, which also inhibits DPD, though less potently; UFT has a higher content of tegafur than that in TS-1. Tegafur 36-43 dihydropyrimidine dehydrogenase Homo sapiens 77-80 17603216-4 2007 METHODS: We developed a model incorporating the inhibition of DPD by gimeracil and uracil, and fitted the model to the observed kinetics of tegafur and 5-FU after the administration of TS-1 and UFT. Tegafur 140-147 dihydropyrimidine dehydrogenase Homo sapiens 62-65 17952005-0 2007 Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. Tegafur 98-105 dihydropyrimidine dehydrogenase Homo sapiens 0-31 17143493-6 2007 The TS activity was decreased by NAC with UFT, and the addition of CPA resulted in an increased inhibition of TS activity. Tegafur 42-45 thymidylate synthetase Homo sapiens 4-6 17143493-7 2007 In contrast, DPD activity was increased by NAC with UFT administration, but its increased activity was significantly inhibited by the addition of CPA. Tegafur 52-55 dihydropyrimidine dehydrogenase Homo sapiens 13-16 17006925-2 2006 This randomized controlled trial evaluated whether postoperative adjuvant therapy with oral uracil-tegafur (UFT) prevents recurrence of HCC. Tegafur 108-111 HCC Homo sapiens 136-139 17143493-0 2007 Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. Tegafur 64-71 dihydropyrimidine dehydrogenase Homo sapiens 86-117 17143493-1 2007 The present study assesses the effects of neo-adjuvant chemotherapy (NAC) with uracil and tegafur (UFT) alone vs UFT plus cyclophosphamide (CPA), on the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in breast cancer tissues. Tegafur 90-97 thymidylate synthetase Homo sapiens 165-185 17143493-1 2007 The present study assesses the effects of neo-adjuvant chemotherapy (NAC) with uracil and tegafur (UFT) alone vs UFT plus cyclophosphamide (CPA), on the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in breast cancer tissues. Tegafur 99-102 thymidylate synthetase Homo sapiens 165-185 16897985-8 2006 It has a component that enhances the cytotoxic activity of tegafur by inhibiting dihydropyrimidine dehydrogenase (DPD) and also has a component that reduces phosphorylation of 5-fluorouracil in the gastrointestinal tract to potentially reduce toxicity. Tegafur 59-66 dihydropyrimidine dehydrogenase Homo sapiens 81-112 16734727-8 2006 There was a significant correlation between tumor growth inhibition rates against the oral administration of oral-uracil/tegafur (UFT) and OPRT enzyme activity in the human cancer xenografts (r2 = 0.574). Tegafur 121-128 uridine monophosphate synthetase Homo sapiens 139-143 16897968-3 2006 As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts. Tegafur 238-241 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 Mus musculus 19-22 16897985-8 2006 It has a component that enhances the cytotoxic activity of tegafur by inhibiting dihydropyrimidine dehydrogenase (DPD) and also has a component that reduces phosphorylation of 5-fluorouracil in the gastrointestinal tract to potentially reduce toxicity. Tegafur 59-66 dihydropyrimidine dehydrogenase Homo sapiens 114-117 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 80-87 dihydropyrimidine dehydrogenase Homo sapiens 191-222 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 80-87 dihydropyrimidine dehydrogenase Homo sapiens 224-227 16897985-10 2006 In addition, considerable ethnic differences in the tolerated doses of S-1 have been considered related to varying efficiency rates of conversion of tegafur to 5-fluorouracil by the CYP450 enzyme system. Tegafur 149-156 proteasome 26S subunit, non-ATPase 1 Homo sapiens 71-74 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 89-91 dihydropyrimidine dehydrogenase Homo sapiens 191-222 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 89-91 dihydropyrimidine dehydrogenase Homo sapiens 224-227 16897985-11 2006 The varying efficiency is thought to be due to the presence of certain polymorphisms in the CYP2A6 gene responsible for metabolizing tegafur to 5-fluorouracil. Tegafur 133-140 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 92-98 16897986-3 2006 S-1 is an oral 5-FU anti-tumor drug that combines three pharmacological agents: tegafur, 5-chloro-2,4-dihydroxypyridine, which inhibits dihydropyrimidine dehydrogenase activity, and potassium oxonate, which reduces gastrointestinal toxicity. Tegafur 80-87 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 16145066-1 2005 PURPOSE: The conversion rate of tegafur (a component of S-1) to fluorouracil (FU) differs in Asians and whites because of polymorphic differences in the CYP2A6 gene. Tegafur 32-39 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 153-159 16549996-2 2006 A single oral dose of S-1, 50 mg as tegafur, was administered, serial peripheral blood samples were collected, and the concentrations of 5-fluorouracil (5-FU) and gimeracil (CDHP) were measured. Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 22-25 16447654-7 2005 MFUT- II showed alpha1,2-FT activity with both asialo-monosialoteterahexosyl ganglioside (GA1) and monosialoteterahexosyl ganglioside (GM1) as substrates to produce fucosyl GA1(FGA1) and fucosyl GM1(FGM1), respectively, but MFUT- I only showed alpha1,2-FT activity with GA1. Tegafur 25-27 coenzyme Q10A Mus musculus 135-138 16619581-3 2006 The purpose of this study was to examine whether Jab1 expression can be a useful prognostic factor in OSCC patients treated by 1 M Tegafur and 4 M uracil (UFT) in combination with radiation. Tegafur 131-138 COP9 signalosome subunit 5 Homo sapiens 49-53 16619581-3 2006 The purpose of this study was to examine whether Jab1 expression can be a useful prognostic factor in OSCC patients treated by 1 M Tegafur and 4 M uracil (UFT) in combination with radiation. Tegafur 155-158 COP9 signalosome subunit 5 Homo sapiens 49-53 15785747-6 2005 In patients with stage II-III NSCLCs, furthermore, the survival of UFT (a combination of tegafur and uracil)-treated patients with TS-negative tumours was significantly better than those of any other patients. Tegafur 89-96 thymidylate synthetase Homo sapiens 131-133 15944764-1 2005 The purposes of this study were to evaluate the antitumor activity of S-1 (1 M tegafur, 0.4 M 5-chloro-2,4-dihydroxypyridine and 1 M potassium oxonate) on human lung tumor xenografts, as compared with other fluoro-pyrimidines, and to investigate the relationships between fluoropyrimidine antitumor activities and four distinct enzymatic activities involved in the phosphorylation and degradation pathways of 5-fluorouracil (5-FU) metabolism. Tegafur 79-86 proteasome 26S subunit, non-ATPase 1 Homo sapiens 70-73 15944764-4 2005 Cluster analysis, on the basis of antitumor activity, indicated that S-1/UFT and 5"-DFUR/capecitabine/5-FU could be classified into another group. Tegafur 73-76 proteasome 26S subunit, non-ATPase 1 Homo sapiens 69-72 15598584-6 2005 Furthermore, heterogeneous expression of DPD was more effective than homogeneous expression of DPD in neoplastic cells when evaluated in patients treated with chemotherapy including tegafur/uracil (UFT). Tegafur 182-196 dihydropyrimidine dehydrogenase Homo sapiens 41-44 15598584-6 2005 Furthermore, heterogeneous expression of DPD was more effective than homogeneous expression of DPD in neoplastic cells when evaluated in patients treated with chemotherapy including tegafur/uracil (UFT). Tegafur 198-201 dihydropyrimidine dehydrogenase Homo sapiens 41-44 15160338-1 2004 BACKGROUND: The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. Tegafur 163-170 proteasome 26S subunit, non-ATPase 1 Homo sapiens 141-144 15297391-1 2004 PURPOSE: The oral fluoropyrimidine S-1, which consists of a mixture of a 5-fluorouracil (5-FU) prodrug (tegafur), a dihydropyrimidine dehydrogenase inhibitor [5-chloro-2,4-dihydroxypyrimidine (CDHP)], and an inhibitor of orotate phosphoribosyltransferase [potassium oxonate (oxonic acid)], was developed to increase the feasibility and therapeutic index of 5-FU administered orally. Tegafur 104-111 proteasome 26S subunit, non-ATPase 1 Homo sapiens 35-38 15363468-9 2004 The goal of this article is to review the literature concerning the treatment of elderly patients with UFT, an orally administered dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine. Tegafur 103-106 dihydropyrimidine dehydrogenase Homo sapiens 131-162 15363468-9 2004 The goal of this article is to review the literature concerning the treatment of elderly patients with UFT, an orally administered dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine. Tegafur 103-106 dihydropyrimidine dehydrogenase Homo sapiens 164-167 15218314-0 2004 Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Tegafur 151-158 thymidylate synthetase Homo sapiens 4-24 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Tegafur 92-99 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Tegafur 101-109 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15550867-1 2004 BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. Tegafur 127-134 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 15550867-1 2004 BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. Tegafur 136-138 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 15224197-0 2004 Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Tegafur 59-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 48-51 15331922-1 2004 OBJECTIVE: S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate (Oxo), a reducer of gastrointestinal toxicity. Tegafur 103-110 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 15331922-1 2004 OBJECTIVE: S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate (Oxo), a reducer of gastrointestinal toxicity. Tegafur 112-114 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 15218314-1 2004 OBJECTIVE: To assess the thymidylate synthase protein (TS) in tumor cells of resected gastric cancer patients treated with adjuvant tegafur (TG), we reviewed the outcome of 94 randomized patients treated either with adjuvant TG plus mitomycin C (MMC) or MMC alone. Tegafur 132-139 thymidylate synthetase Homo sapiens 25-45 15218314-1 2004 OBJECTIVE: To assess the thymidylate synthase protein (TS) in tumor cells of resected gastric cancer patients treated with adjuvant tegafur (TG), we reviewed the outcome of 94 randomized patients treated either with adjuvant TG plus mitomycin C (MMC) or MMC alone. Tegafur 141-143 thymidylate synthetase Homo sapiens 25-45 12818351-5 2003 Expression of P-gp in this mutant confers cross-resistance to mitomycin C, tegafur, daunorubicin, rhodamine 6G, tetraphenylphosphonium bromide and ciprofloxacin. Tegafur 75-82 phosphoglycolate phosphatase Mus musculus 14-18 14636615-0 2003 Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma. Tegafur 101-115 thymidylate synthetase Homo sapiens 40-60 14636615-0 2003 Predictive value of immunohistochemical thymidylate synthase expression for histological response to Tegafur/Uracil (UFT) in oral squamous cell carcinoma. Tegafur 117-120 thymidylate synthetase Homo sapiens 40-60 14636615-2 2003 We investigated the relationship between the level of tumoural TS expression and response to tegafur/uracil (UFT) in 26 patients with oral squamous cell carcinoma. Tegafur 93-100 thymidylate synthetase Homo sapiens 63-65 14636615-2 2003 We investigated the relationship between the level of tumoural TS expression and response to tegafur/uracil (UFT) in 26 patients with oral squamous cell carcinoma. Tegafur 109-112 thymidylate synthetase Homo sapiens 63-65 14551502-2 2003 DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid). Tegafur 89-92 dihydropyrimidine dehydrogenase Homo sapiens 0-3 14663640-2 2003 S-1 is an oral fluoropyrimidine derivative combining tegafur with the modulators 5-chloro-2,4-dihydroxypyrimidine (a potent dihydropyrimidine dehydrogenase inhibitor), and potassium oxonate (an orotate phosphoribosyl transferase inhibitor), in a molar ratio of 1 : 0.4 : 1. Tegafur 53-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 14650374-1 2003 OBJECTIVE: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. Tegafur 53-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 14650374-1 2003 OBJECTIVE: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. Tegafur 62-64 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 12538461-1 2003 PURPOSE: Our purpose in the study was to determine the maximum tolerated dose and dose-limiting toxicity and investigate the clinical pharmacology of S-1, a combination of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 172-179 proteasome 26S subunit, non-ATPase 1 Homo sapiens 150-153 12851836-12 2003 DPD inhibitory fluoropyrimidines (DIFs), including uracil plus tegafur (UFT) and tegafur plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate, in a molar ratio of 1:0.4:1 (TS-1), have recently been used in clinical settings. Tegafur 63-70 dihydropyrimidine dehydrogenase Homo sapiens 0-3 12851836-12 2003 DPD inhibitory fluoropyrimidines (DIFs), including uracil plus tegafur (UFT) and tegafur plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate, in a molar ratio of 1:0.4:1 (TS-1), have recently been used in clinical settings. Tegafur 72-75 dihydropyrimidine dehydrogenase Homo sapiens 0-3 12739060-1 2003 S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. Tegafur 30-38 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12739060-1 2003 S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. Tegafur 40-42 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12739060-8 2003 Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Tegafur 32-34 proteasome 26S subunit, non-ATPase 1 Homo sapiens 222-225 12763215-2 2003 S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate (oteracil), at a molar ratio of 1:0.4:1. Tegafur 100-107 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12852361-0 2003 [A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab]. Tegafur 101-104 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 11939265-0 2002 MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil. Tegafur 71-78 lysine methyltransferase 2A Homo sapiens 0-3 15618749-5 2003 The formation of 5-FU from FT in human liver S9 was inhibited over 82% by 8-methoxypsoralen, a CYP2A6-selective inhibitor. Tegafur 27-29 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 95-101 12464897-10 2002 Although TS showed no correlation between tegafur-uracil response and TS labeling index, there was a significant correlation between the tegafur-uracil response and DPD-LI. Tegafur 137-151 dihydropyrimidine dehydrogenase Homo sapiens 165-168 12355409-0 2002 Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer. Tegafur 135-138 dihydropyrimidine dehydrogenase Homo sapiens 20-51 12355409-0 2002 Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer. Tegafur 140-147 dihydropyrimidine dehydrogenase Homo sapiens 20-51 12172220-1 2002 CYP2A6 is known as an enzyme responsible for the metabolism of several clincally used drugs such as tegafur. Tegafur 100-107 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 0-6 12042667-3 2002 Since cytochrome P450 2A6 (CYP2A6) has been reported to metabolize FT to yield 5-fluorouracil (5-FU), it was postulated that the poor metabolic phenotype of patient 1 was caused by mutations of the CYP2A6 gene. Tegafur 67-69 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 6-25 12042667-3 2002 Since cytochrome P450 2A6 (CYP2A6) has been reported to metabolize FT to yield 5-fluorouracil (5-FU), it was postulated that the poor metabolic phenotype of patient 1 was caused by mutations of the CYP2A6 gene. Tegafur 67-69 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 27-33 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. Tegafur 165-172 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. Tegafur 165-172 dihydropyrimidine dehydrogenase Homo sapiens 53-56 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. Tegafur 165-172 tumor necrosis factor Homo sapiens 87-90 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 71-78 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 71-78 dihydropyrimidine dehydrogenase Homo sapiens 139-170 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 71-78 dihydropyrimidine dehydrogenase Homo sapiens 172-175 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 80-82 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 11995458-0 2002 Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Tegafur 46-60 CEA cell adhesion molecule 3 Homo sapiens 13-16 11939265-1 2002 We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Tegafur 153-160 lysine methyltransferase 2A Homo sapiens 58-61 11939265-1 2002 We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Tegafur 153-160 lysine methyltransferase 2A Homo sapiens 92-114 11901535-5 2002 In this study, cisplatin and UFT, a form of uracil and tegafur which is a prodrug of 5-FU, were administered with immunomodulator Polysaccharide K (PSK) to ten patients with colorectal cancer, who showed distant metastasis in the liver or lung, and the serum levels of sIL-2R and sTNF-R1 and the production of gamma-interferon (gamma-INF) and interleukin-10 by peripheral blood mononuclear cells were measured. Tegafur 29-32 TAO kinase 2 Homo sapiens 148-151 11901535-5 2002 In this study, cisplatin and UFT, a form of uracil and tegafur which is a prodrug of 5-FU, were administered with immunomodulator Polysaccharide K (PSK) to ten patients with colorectal cancer, who showed distant metastasis in the liver or lung, and the serum levels of sIL-2R and sTNF-R1 and the production of gamma-interferon (gamma-INF) and interleukin-10 by peripheral blood mononuclear cells were measured. Tegafur 29-32 interleukin 10 Homo sapiens 343-357 11901535-5 2002 In this study, cisplatin and UFT, a form of uracil and tegafur which is a prodrug of 5-FU, were administered with immunomodulator Polysaccharide K (PSK) to ten patients with colorectal cancer, who showed distant metastasis in the liver or lung, and the serum levels of sIL-2R and sTNF-R1 and the production of gamma-interferon (gamma-INF) and interleukin-10 by peripheral blood mononuclear cells were measured. Tegafur 55-62 TAO kinase 2 Homo sapiens 148-151 11816485-4 2002 Based on the enzymatic properties of metastatic tumors, the minimum toxic doses of UFT (17.5 mg/kg/day) as a DPD-inhibitory fluoropyrimidine (DIF), and of 5"-DFUR (120 mg/kg/day) as a non-DIF, were orally administered to mice with pulmonary metastasis of the breast tumor. Tegafur 83-86 dihydropyrimidine dehydrogenase Mus musculus 109-112 12185293-13 2002 The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). Tegafur 154-157 proteasome 26S subunit, non-ATPase 1 Homo sapiens 149-152 11679189-4 2001 Orzel [UFT (uracil:tegafur) plus oral leucovorin] is the first oral DPD-inhibitory fluoropyrimidine. Tegafur 7-10 dihydropyrimidine dehydrogenase Homo sapiens 68-71 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 166-173 thymidylate synthetase Homo sapiens 0-20 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 166-173 thymidylate synthetase Homo sapiens 22-24 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 175-178 thymidylate synthetase Homo sapiens 0-20 12450432-1 2001 Thymidylate synthase (TS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (FUDR), oral 5-FU prodrugs (e.g., uracil/tegafur [UFT], S-1, and capecitabine), and other novel folate-based drugs (e.g., raltitrexed, pemetrexed, and nolatrexed). Tegafur 175-178 thymidylate synthetase Homo sapiens 22-24 11729480-0 2001 [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity]. Tegafur 77-80 dihydropyrimidine dehydrogenase Homo sapiens 99-102 10699888-1 2000 BACKGROUND: This study examined the effect of tegafur, a depot of 5-fluorouracil, in human colorectal carcinomas in terms of apoptosis, cell proliferation, and expression of p53 gene and angiogenesis-related molecules. Tegafur 46-53 tumor protein p53 Homo sapiens 174-177 11353746-3 2001 Of 12 cDNA-expressed rat P450 enzymes tested, CYP1A2, CYP3A1, and CYP2C11 had high 5-FU formation rates from 100 microM and 1.0 mM tegafur concentrations. Tegafur 131-138 cytochrome P450, family 1, subfamily a, polypeptide 2 Rattus norvegicus 46-52 11353746-3 2001 Of 12 cDNA-expressed rat P450 enzymes tested, CYP1A2, CYP3A1, and CYP2C11 had high 5-FU formation rates from 100 microM and 1.0 mM tegafur concentrations. Tegafur 131-138 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 Rattus norvegicus 54-60 11353746-3 2001 Of 12 cDNA-expressed rat P450 enzymes tested, CYP1A2, CYP3A1, and CYP2C11 had high 5-FU formation rates from 100 microM and 1.0 mM tegafur concentrations. Tegafur 131-138 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 66-73 11353746-6 2001 Orally administered tegafur (100 mg/kg daily for 20 days) caused the induction of CYP2B (5-fold) and of CYP1A and CYP3A (approximately 2-fold) and of 5-FU formation (approximately 2-fold) in rat liver microsomes. Tegafur 20-27 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 114-119 11497250-1 2001 S-1 is a new oral formulation of 5-fluorouracil (5-FU) containing 1 M tegafur and 0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP) and 1 M potassium oxonate (Oxo). Tegafur 70-77 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 11376561-2 2001 CYP2A6-expressing cells (DLD-1 / CYP2A6 cells) more efficiently catalyzed the conversion of FT to 5-fluorouracil (5-FU) (2.6-fold) and the 7-hydroxylation of coumarin (7.9-fold) than cells transfected with a null construct (DLD-1 / null cells). Tegafur 92-94 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 0-6 11376561-2 2001 CYP2A6-expressing cells (DLD-1 / CYP2A6 cells) more efficiently catalyzed the conversion of FT to 5-fluorouracil (5-FU) (2.6-fold) and the 7-hydroxylation of coumarin (7.9-fold) than cells transfected with a null construct (DLD-1 / null cells). Tegafur 92-94 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 33-39 11354285-9 2001 RESULTS: In the group treated only with enteric-coated tegafur/uracil, the median survival time and 1 and 2 year survival rates were 12.13 months and 55.3 and 36.9%, respectively. Tegafur 55-62 WD repeat and HMG-box DNA binding protein 1 Homo sapiens 96-107 11279841-7 2001 When PSA rose again, we started oral chemotherapy with tegafur.uracil. Tegafur 55-62 kallikrein related peptidase 3 Homo sapiens 5-8 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. Tegafur 20-23 vascular endothelial growth factor A Homo sapiens 227-261 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. Tegafur 20-23 vascular endothelial growth factor A Homo sapiens 263-267 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. Tegafur 20-23 fibroblast growth factor 2 Homo sapiens 288-314 11911014-3 2001 Here we report that UFT was more effective than other fluorinated pyrimidines such as 5-FU and doxifluridine (5"-DFUR) in blocking the angiogenic responses elicited by five human cancer cell lines which produced high levels of vascular endothelial growth factor (VEGF), but no detectable fibroblast growth factor-2 (FGF-2) in vitro. Tegafur 20-23 fibroblast growth factor 2 Homo sapiens 316-321 11710628-6 2001 RESULTS: Although docetaxel (5 mg/kg) alone did not decrease either tumor growth or serum IL-6 levels, docetaxel (5 mg/kg) plus 5"-dFUrd or tegafur enhanced tumor growth inhibition and decreased serum IL-6 levels more than 5"-dFUrd or tegafur alone. Tegafur 140-147 interleukin 6 Homo sapiens 201-205 11525030-1 2001 We report the a case of 60-year-old male whose final finding was curability C and stage IV scirrhus type gastric cancer because of N3, CY1 and DM (+) treated with a novel oral anticancer drug composed of tegafur (FT), Gimeracil (CDHP) and Oteracil Potassium (Oxo) in a molar ratio of 1:04:1 after operation. Tegafur 204-211 cadherin 3 Homo sapiens 229-233 11201382-4 2001 TS-1, which contains tegafur and dihydroxypyridine (CDHP), a potent DPD inhibitor, is a promising anticancer drug. Tegafur 21-28 thymidylate synthetase Homo sapiens 0-2 11219978-2 2001 Tegafur, a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU by the hepatic cytochrome P450 pathway, whereas uracil enhances the half-life of converted 5-FU leading to prolonged exposure and higher intracellular concentration of 5-FU by inhibiting dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism. Tegafur 0-7 dihydropyrimidine dehydrogenase Homo sapiens 253-284 11219978-2 2001 Tegafur, a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU by the hepatic cytochrome P450 pathway, whereas uracil enhances the half-life of converted 5-FU leading to prolonged exposure and higher intracellular concentration of 5-FU by inhibiting dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism. Tegafur 0-7 dihydropyrimidine dehydrogenase Homo sapiens 286-289 11095583-1 2000 Tegafur, an anticancer prodrug, is bioactivated to 5-fluorouracil (5-FU) mainly by cytochrome P450 (P450) enzymes. Tegafur 0-7 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 94-98 11095583-1 2000 Tegafur, an anticancer prodrug, is bioactivated to 5-fluorouracil (5-FU) mainly by cytochrome P450 (P450) enzymes. Tegafur 0-7 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 100-104 11095583-2 2000 The conversion from tegafur into 5-FU catalyzed by human liver microsomal P450 enzymes was investigated. Tegafur 20-27 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 74-78 11106261-0 2000 Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Tegafur 17-24 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 59-79 10974399-0 2000 Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells. Tegafur 26-33 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 94-97 11098498-9 2000 Dorsal air sac assay revealed that UFT, 5-FU, and gamma-hydroxybutyric acid strongly inhibited the angiogenesis induced by recombinant human VEGF. Tegafur 35-38 vascular endothelial growth factor A Homo sapiens 141-145 10913935-7 2000 The time course of IL-6 and FT(3 )concentration seemed to be closely linked. Tegafur 28-30 interleukin 6 Homo sapiens 19-23 10901361-2 2000 This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Tegafur 131-138 proteasome 26S subunit, non-ATPase 1 Homo sapiens 111-114 10790998-1 2000 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 49-56 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 10790998-1 2000 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 58-60 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 10769701-3 2000 To investigate a cell adhesion molecule, CD44, which may very well contribute to the pathogenesis of metastasis, we examined the association of CD44 and the thymidylate synthase inhibition rate(TSIR) with prognosis, and examined the expression of apoptosis in patients who were administrated tegafur-uracil before surgery for colorectal cancer. Tegafur 292-306 CD44 molecule (Indian blood group) Homo sapiens 41-45 10769701-13 2000 CONCLUSION: Based on our results for TSIR, Tegafur-uracil may induce apoptosis of tumor cells in patients by the inhibition of thymidylate synthase. Tegafur 43-57 thymidylate synthetase Homo sapiens 127-147 10430334-2 1999 Despite post-operative treatment with oral Tegafur (400 mg/m2/day), CEA level increased gradually beginning 15 months after surgery. Tegafur 43-50 pregnancy specific beta-1-glycoprotein 2 Homo sapiens 68-71 10573104-0 1999 Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Tegafur 73-76 estrogen receptor 1 Homo sapiens 122-139 10573104-2 1999 The effectiveness of combining mitomycin C (MMC), tamoxifen (TAM), and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) was evident in patients with estrogen receptor-positive (ER+) breast cancers. Tegafur 71-107 estrogen receptor 1 Homo sapiens 147-164 10573104-2 1999 The effectiveness of combining mitomycin C (MMC), tamoxifen (TAM), and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) was evident in patients with estrogen receptor-positive (ER+) breast cancers. Tegafur 109-116 estrogen receptor 1 Homo sapiens 147-164 10595802-4 1999 Recently, investigators have identified at least five compounds -capecitabine, UFT (tegafur plus uracil), eniluracil, S-1, and BOF-A2-that inhibit, destroy, inactivate, or bypass DPD"s activity. Tegafur 79-82 dihydropyrimidine dehydrogenase Homo sapiens 179-182 10595802-4 1999 Recently, investigators have identified at least five compounds -capecitabine, UFT (tegafur plus uracil), eniluracil, S-1, and BOF-A2-that inhibit, destroy, inactivate, or bypass DPD"s activity. Tegafur 84-91 dihydropyrimidine dehydrogenase Homo sapiens 179-182 10697523-4 1999 Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells. Tegafur 30-33 thymidylate synthetase Rattus norvegicus 158-178 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 92-99 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 92-99 dihydropyrimidine dehydrogenase Homo sapiens 205-236 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 92-99 dihydropyrimidine dehydrogenase Homo sapiens 238-241 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 101-103 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 101-103 dihydropyrimidine dehydrogenase Homo sapiens 205-236 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 101-103 dihydropyrimidine dehydrogenase Homo sapiens 238-241 10442372-0 1999 UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Tegafur 0-3 estrogen receptor 1 Homo sapiens 47-49 10226549-4 1999 Six-week oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) reduced the total number of colorectal tumors, with the reduction of thymidylate synthetase activity in the poorly-differentiated type, though the mRNA expression of thymidylate synthetase and thymidine kinase differed little between the groups with or without UFT treatment. Tegafur 32-68 thymidylate synthetase Rattus norvegicus 171-193 10363582-0 1999 p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Tegafur 73-80 tumor protein p53 Homo sapiens 0-3 10363584-0 1999 Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Tegafur 26-33 proteasome 26S subunit, non-ATPase 1 Homo sapiens 94-97 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. Tegafur 9-16 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. Tegafur 18-20 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10211555-8 1999 These results indicate that cisplatin and UFT as a single agent promote the chemotactic activities and the production of MMP-9 in non-metastatic fibrosarcoma cells, resulting in the conversion to highly metastatic ones, and that cisplatin and UFT in combination failed to promote the chemotactic activities and the conversion. Tegafur 42-45 matrix metallopeptidase 9 Mus musculus 121-126 10226549-4 1999 Six-week oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) reduced the total number of colorectal tumors, with the reduction of thymidylate synthetase activity in the poorly-differentiated type, though the mRNA expression of thymidylate synthetase and thymidine kinase differed little between the groups with or without UFT treatment. Tegafur 32-68 thymidylate synthetase Rattus norvegicus 268-290 10226549-4 1999 Six-week oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) reduced the total number of colorectal tumors, with the reduction of thymidylate synthetase activity in the poorly-differentiated type, though the mRNA expression of thymidylate synthetase and thymidine kinase differed little between the groups with or without UFT treatment. Tegafur 97-100 thymidylate synthetase Rattus norvegicus 171-193 10226549-4 1999 Six-week oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) reduced the total number of colorectal tumors, with the reduction of thymidylate synthetase activity in the poorly-differentiated type, though the mRNA expression of thymidylate synthetase and thymidine kinase differed little between the groups with or without UFT treatment. Tegafur 97-100 thymidylate synthetase Rattus norvegicus 268-290 9840729-2 1998 S-1 is an oral combined form of 1 M tegafur [a prodrug of 5-fluorouracil (5-FU)], 0.4 M 5-chloro-2,4-dihydroxypyridine (a reversible inhibitor of dihydropyrimidine dehydrogenase) and 1 M potassium oxonate (an inhibitor of orotate phosphoribosyltransferase). Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9239165-0 1997 [Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer--concomitant effects based on the thymidylate synthase inhibitory rat]. Tegafur 48-51 thymidylate synthetase Homo sapiens 140-160 9893658-0 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Tegafur 76-83 proteasome 26S subunit, non-ATPase 1 Homo sapiens 67-70 9893658-1 1998 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 49-56 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9893658-1 1998 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 58-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9679577-3 1998 To achieve high activity and low toxicity, S-1 was designed, in which tegafur, prodrug of 5-FU, was combined with two classes of modulators. Tegafur 70-77 proteasome 26S subunit, non-ATPase 1 Homo sapiens 43-46 9703363-5 1998 5-FUra and Tegafur inhibited the increase of NNMT activity at higher concentrations. Tegafur 11-18 nicotinamide N-methyltransferase Mus musculus 45-49 9635926-1 1998 Chronic oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil suppressed thymidylate synthetase (TS) gene expression followed by reduction of TS activity in rat mammary tumors induced with 7,12-dimethylbenz[a]anthracene. Tegafur 31-67 thymidylate synthetase Rattus norvegicus 106-128 9635926-1 1998 Chronic oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil suppressed thymidylate synthetase (TS) gene expression followed by reduction of TS activity in rat mammary tumors induced with 7,12-dimethylbenz[a]anthracene. Tegafur 31-67 thymidylate synthetase Rattus norvegicus 130-132 9635926-1 1998 Chronic oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil suppressed thymidylate synthetase (TS) gene expression followed by reduction of TS activity in rat mammary tumors induced with 7,12-dimethylbenz[a]anthracene. Tegafur 31-67 thymidylate synthetase Rattus norvegicus 175-177 9052401-7 1997 They were more sensitive than parental PC-9 or PC9-D1 cells not only to 5"-DFUR and tegafur but also to 5-FU. Tegafur 84-91 proprotein convertase subtilisin/kexin type 9 Homo sapiens 47-50 9140762-0 1997 Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. Tegafur 39-46 proteasome 26S subunit, non-ATPase 1 Homo sapiens 17-20 9140762-1 1997 A high-performance liquid chromatography (HPLC) and gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICI-MS) method was developed for the analysis of the combined antitumor drug S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and active metabolite 5-fluorouracil in human plasma and urine. Tegafur 209-216 proteasome 26S subunit, non-ATPase 1 Homo sapiens 204-207 9021668-1 1996 S-1 is a new antineoplastic agent of a fluorinated pyrimidine derivative containing tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1 with the aim of prolonging the effective plasma concentration of 5-fluorouracil (5-FU) and reducing its dose-limiting gastrointestinal toxicity. Tegafur 84-91 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9021668-1 1996 S-1 is a new antineoplastic agent of a fluorinated pyrimidine derivative containing tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1 with the aim of prolonging the effective plasma concentration of 5-fluorouracil (5-FU) and reducing its dose-limiting gastrointestinal toxicity. Tegafur 93-95 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9021669-2 1996 S-1 contains tegafur (FT), CDHP, and potassium oxonate (Oxo) in a molecular ratio of 1:0.4:1. Tegafur 13-20 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 9021669-2 1996 S-1 contains tegafur (FT), CDHP, and potassium oxonate (Oxo) in a molecular ratio of 1:0.4:1. Tegafur 22-24 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 7487125-0 1995 [UFT/CDDP preoperative chemotherapy for progressive gastric cancer--histological antitumor effects and thymidylate synthase inhibition rate]. Tegafur 1-4 thymidylate synthetase Homo sapiens 103-123 8673994-7 1996 We conducted a Phase II study on patients with gastric carcinoma using the combination VP-16-LV-UFT. Tegafur 96-99 host cell factor C1 Homo sapiens 87-92 8680114-1 1996 The modulating effect of recombinant human interferon alpha-2a (IFN) on the antitumor activity of UFT, a mixed compound of tegafur and uracil at a molar ratio of 1:4, was investigated against SC-1-NU, a human gastric cancer xenograft serially transplanted in nude mice. Tegafur 123-130 interferon alpha 1 Homo sapiens 64-67 8765432-0 1996 Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Tegafur 65-79 thymidylate synthetase Homo sapiens 0-20 8765432-0 1996 Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Tegafur 81-84 thymidylate synthetase Homo sapiens 0-20 7552812-1 1995 Previous work in our laboratory showed that UFT (mixed compound of tegafur and uracil, molar ratio 1:4, respectively) caused the prolonged reduction of dTTP in L1210 leukemia cells in comparison with 5-fluorouracil (5-FU). Tegafur 67-74 ttp Drosophila melanogaster 152-156 8464418-0 1993 [Changes of the number of FdUMP binding sites of thymidylate synthase and folate pools in human colorectal carcinomas following the administration of tegafur and uracil: preliminary report]. Tegafur 150-157 thymidylate synthetase Homo sapiens 49-69 8468974-0 1993 Dependence of the thymidylate synthase inhibition rate on the interval after the last administration of tegafur in sigmoid colon cancer patients. Tegafur 104-111 thymidylate synthetase Homo sapiens 18-38 1992915-0 1991 [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT]. Tegafur 117-124 thymidylate synthetase Homo sapiens 56-76 1391859-0 1992 [Biochemical bases of ftorafur-potentiating effects of perfluorodecalin, inducer of cytochrome P-450 dependent microsomal monooxygenases]. Tegafur 22-30 cytochrome P450, family 21, subfamily a, polypeptide 1 Mus musculus 84-100 1519926-0 1992 [Neo-adjuvant chemotherapy with tegafur suppository for rectal cancer--evaluation of the antitumor effects, tissue levels of 5-FU and inhibition of thymidylate synthase. Tegafur 32-39 thymidylate synthetase Homo sapiens 148-168 1802023-1 1991 Effects of the immunomodulator PSK on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) to 5-fluorouracil (5-FU) were examined in 10 patients with advanced gastric cancer and who had undergone curative resection. Tegafur 56-92 TAO kinase 2 Homo sapiens 31-34 1802023-1 1991 Effects of the immunomodulator PSK on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) to 5-fluorouracil (5-FU) were examined in 10 patients with advanced gastric cancer and who had undergone curative resection. Tegafur 94-101 TAO kinase 2 Homo sapiens 31-34 2241188-5 1990 From the results obtained, reasonable consecutive administration of tegafur would be possible by immunohistochemical checking the P450 in the gastric wall. Tegafur 68-75 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 130-134 1767795-1 1991 Juzen-taiho-to (JTT; [Shi-quan-da-bu-tang], a Japanese modified Chinese herbal prescription) in combination with an anticancer drug UFT (5-fluorouracil derivative) prevented the body weight loss and the induction of the colonic cancer in rats treated with a chemical carcinogen 1,2-dimethylhydrazine (DMH), and suppressed markedly the activity of thymidylate synthetase (TS) involved in the de novo pathway of pyrimidine synthesis in colonic cancer induced by DMH. Tegafur 132-135 thymidylate synthetase Rattus norvegicus 347-369 35601927-3 2022 Methods: The Japan Clinical Oncology Group (JCOG) 0707, a phase 3 trial comparing the benefits of UFT and S-1 (tegafur-gimeracil-oteracil) in patients with completely resected stage I NSCLC (T1 >2 cm and T2 in the TNM sixth edition), was conducted in Japan. Tegafur 98-101 teneurin transmembrane protein 1 Homo sapiens 214-217 2118939-3 1990 1) Thymidylate synthetase (TS), DNA-synthesizing enzyme in de novo pathway of pyrimidine metabolism, increased to approximately 7-fold that of normal control colon in DMH-induced colon carcinomas in activity, but was markedly reduced to 48% of that in the carcinomas by administration of UFT. Tegafur 288-291 thymidylate synthetase Rattus norvegicus 3-25 34845792-0 2022 ACTN4 gene amplification is a predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas. Tegafur 82-85 actinin alpha 4 Homo sapiens 0-5 35629045-1 2022 This study aimed to explore the safety and efficacy of neoadjuvant SCRT and tegafur-uracil/leucovorin plus oxaliplatin (TEGAFOX) for LARC in comparison to those of the modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX-6) regimen. Tegafur 76-83 C-C motif chemokine ligand 20 Homo sapiens 133-137 3131462-1 1988 The effect of calmodulin antagonists (W-5 and W-7) on antitumor activity of 1-(2-Tetrahydrofuryl)-5-fluorouracil (Tegafur; FT) and FT plus uracil (UFT) was examined by using nude mice bearing human ovarian carcinoma (KF cells). Tegafur 76-112 calmodulin 2 Mus musculus 14-24 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 134-137 thymidylate synthetase Homo sapiens 59-79 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 134-137 thymidylate synthetase Homo sapiens 81-83 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 170-206 thymidylate synthetase Homo sapiens 59-79 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 170-206 thymidylate synthetase Homo sapiens 81-83 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 208-215 thymidylate synthetase Homo sapiens 59-79 2495166-1 1989 The authors examined the relationship between the level of thymidylate synthase (TS) and the sensitivity to 5-fluorouracil (5-FU) and UFT, a combined oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil in a molar ratio of 1:4. Tegafur 208-215 thymidylate synthetase Homo sapiens 81-83 2534895-2 1989 Ftorafur was injected in amounts of 2.3 mg/100 g of body weight, and a significant reduction was noted in the secretion of bicarbonates, amylase and lipase by the pancreas of the animals. Tegafur 0-8 lipase G, endothelial type Rattus norvegicus 149-155 3337530-5 1988 UFT, 5-fluorouracil, mitomycin-C and adriamycin were administered to gastrointestinal cancer patients regularly, but our SRC-assay showed a high sensitivity rate for UFT and 5-fluorouracil but a low sensitivity rate for mitomycin-C and adriamycin. Tegafur 0-3 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 121-124 2447833-10 1988 When the administration of UFT (10 mg or 20 mg/kg/day) was started simultaneously with feeding 3"-MeDAB diet, the primary reaction was somewhat suppressed, and after week 11 development of hepatoma and elevation of AFP were markedly inhibited. Tegafur 27-30 alpha-fetoprotein Rattus norvegicus 215-218 2436576-9 1987 4) More than 3 months after 5-FU or tegafur administration, significant elevations of serum T3, T4 and TBG concentrations were demonstrated in cancer patients, compared to pre-treatment values or those within 2 months after therapy, although there were no significant changes in serum thyroglobulin and TSH levels before and after therapy. Tegafur 36-43 serpin family A member 7 Homo sapiens 103-106 3120645-7 1987 Values of the skin reaction after dosing were significantly (p less than 0.05) high compared to those before dosing in groups A and C. Concentrations of Tegafur and 5-FU in serum reached to the peak 2 hr later and were maintained high enough to expect clinical responses even at 4 hr after administration in groups A and B. Tegafur 153-160 PEAK1 related, kinase-activating pseudokinase 1 Homo sapiens 194-200 6409396-1 1983 There are two major R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) activation pathways to 5-fluorouracil, one that is mediated by microsomal cytochrome P-450 oxidation at C-5" of the tetrahydrofuran moiety and one that is mediated by soluble enzymes. Tegafur 65-73 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 149-165 2430121-0 1986 [Alpha-fetoprotein producing gastric cancer responding to combined chemotherapy with UFT and adriamycin]. Tegafur 85-88 alpha fetoprotein Homo sapiens 1-18 2430121-1 1986 A case of AFP producing gastric carcinoma with liver metastasis that showed marked response to combined chemotherapy with UFT and Adriamycin (ADM) is reported. Tegafur 122-125 alpha fetoprotein Homo sapiens 10-13 6438379-0 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil. Tegafur 49-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-16 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 49-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-16 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 49-88 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-16 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 49-88 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 192-197 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 49-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 181-197 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 90-92 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-16 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 90-92 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-16 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 90-92 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 192-197 6438379-1 1984 Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) was investigated in a reconstituted system containing purified phenobarbital-inducible cytochrome P-450 (P-450(1)) or 3-methylcholanthrene-inducible cytochrome P-450 (P-448(1)). Tegafur 90-92 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 181-197 6426401-4 1984 Thymidylate synthase was inhibited more severely by oral administration of UFT (30 mg/kg). Tegafur 75-78 thymidylate synthetase Homo sapiens 0-20 6409396-1 1983 There are two major R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) activation pathways to 5-fluorouracil, one that is mediated by microsomal cytochrome P-450 oxidation at C-5" of the tetrahydrofuran moiety and one that is mediated by soluble enzymes. Tegafur 65-73 complement C5 Homo sapiens 179-182 208905-4 1978 N1-(2"-Tetrahydrofuryl)-5-fluorouracil (FT-207), 90 mg/kg body weight, intraperitoneally daily for 4 weeks, suppressed the growth of Co-3 and St-15 slightly but with statistical significance, and had no effect on St-4. Tegafur 40-46 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 Homo sapiens 213-217 6819375-3 1982 The effect of lipopolysaccharide (obtained from Escherichia coli, LPS) on the antitumor activity, acute toxicity and metabolism of tegafur was investigated in mice in comparison with 5-fluorouracil (5-FU). Tegafur 131-138 toll-like receptor 4 Mus musculus 66-69 6819375-5 1982 On the acute toxicity of tegafur or 5-FU, the lethality of the former was decreased and that of the latter was enhanced by the pretreatment with LPS 24 hr before. Tegafur 25-32 toll-like receptor 4 Mus musculus 145-148 6819375-8 1982 In the liver and kidneys of LPS-treated mice, the level of 5-FU after the administration of tegafur or 5-FU was higher, and its conversion of 5-FU to fluorouridine (FUR) was lower than that of control mice. Tegafur 92-99 toll-like receptor 4 Mus musculus 28-31 6819375-10 1982 It can, therefore, be presumed that the antitumor activity of tegafur was affected with LPS as a result of inhibition of conversion from tegafur to 5-FU or from 5-FU to FUR mainly according to depression in the hepatic drug-metabolism. Tegafur 62-69 toll-like receptor 4 Mus musculus 88-91 6819375-10 1982 It can, therefore, be presumed that the antitumor activity of tegafur was affected with LPS as a result of inhibition of conversion from tegafur to 5-FU or from 5-FU to FUR mainly according to depression in the hepatic drug-metabolism. Tegafur 137-144 toll-like receptor 4 Mus musculus 88-91 6797104-1 1981 Phenobarbital stimulates the induction of liver microsomal drug-metabolizing enzyme, namely, cytochrome P-450, which enhances the rate of conversion of FT-207 to 5-FU, the active substance. Tegafur 152-158 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 93-109 378768-1 1979 The effect of two antitumour drugs, ftorafur (Ft) and 5-fluorouracil (5-FU) on chromosomes of human tumour cells (strain CA-1) was studied in vitro. Tegafur 36-44 carbonic anhydrase 1 Homo sapiens 121-125 357721-2 1978 Convenient and efficient methods were developed for preparing 1-(tetrahydro-2-furanyl)-5-fluorouracil (Thf-FU, 3) [trade name, Futraful (Ftorafur) or FT-207], which is used clinically as an antitumor agent, and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil (Thf2-FU, 4). Tegafur 62-101 thin fur Mus musculus 103-106 357721-2 1978 Convenient and efficient methods were developed for preparing 1-(tetrahydro-2-furanyl)-5-fluorouracil (Thf-FU, 3) [trade name, Futraful (Ftorafur) or FT-207], which is used clinically as an antitumor agent, and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil (Thf2-FU, 4). Tegafur 137-145 thin fur Mus musculus 103-106 357721-2 1978 Convenient and efficient methods were developed for preparing 1-(tetrahydro-2-furanyl)-5-fluorouracil (Thf-FU, 3) [trade name, Futraful (Ftorafur) or FT-207], which is used clinically as an antitumor agent, and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil (Thf2-FU, 4). Tegafur 150-156 thin fur Mus musculus 103-106 33887129-12 2021 In the PCOS group, fetuin-A was positively correlated with TT, FT, FAI and androstenedione and negatively correlated with SHBG. Tegafur 63-65 alpha 2-HS glycoprotein Homo sapiens 19-27 33259001-9 2021 RFS was significantly longer in patients treated with UFT compared with CMF in patients with HR-/HER2+ subtype (0.30 [0.10-0.88], p = 0.03). Tegafur 54-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 97-101 28520376-7 2012 The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing recommendations for fluoropyrimidines (capecitabine, fluorouracil, and tegafur) based on DPYD genotype (3) (Table 1). Tegafur 155-162 dihydropyrimidine dehydrogenase Homo sapiens 173-177 33059746-13 2020 CONCLUSIONS: FTS B effectively counteracted cognitive decline by regulating neuroinflammation via NF-kappaB signaling in APP/PS1 mice, providing preliminary experimental evidence that FTS B is a promising therapeutic agent in AD treatment. Tegafur 13-16 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 98-107 33564297-10 2020 After third-line oral S-1 (tegafur/gimeracil/oteracil) administration, the serum AFP level significantly dropped and the patient achieved long-term disease control without relapse, surviving more than 19 months after disease presentation. Tegafur 27-34 alpha fetoprotein Homo sapiens 81-84 33059746-13 2020 CONCLUSIONS: FTS B effectively counteracted cognitive decline by regulating neuroinflammation via NF-kappaB signaling in APP/PS1 mice, providing preliminary experimental evidence that FTS B is a promising therapeutic agent in AD treatment. Tegafur 13-16 presenilin 1 Mus musculus 125-128 32683166-3 2020 In this study, we utilized the core structure 5-fluorouracil (5-FU) or tegafur, a 5-FU prodrug combined through different linkers with resorcinol to generate a series of fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides which inhibit potent Heat Shock Protein 90 (HSP90). Tegafur 71-78 heat shock protein 90 alpha family class A member 1 Homo sapiens 243-264 32683166-3 2020 In this study, we utilized the core structure 5-fluorouracil (5-FU) or tegafur, a 5-FU prodrug combined through different linkers with resorcinol to generate a series of fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides which inhibit potent Heat Shock Protein 90 (HSP90). Tegafur 71-78 heat shock protein 90 alpha family class A member 1 Homo sapiens 266-271 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 dihydropyrimidine dehydrogenase Homo sapiens 147-178 32838518-3 2020 One complex (PFL) that consists of cisplatin, tegafur, and lonidamine exhibits strong cytotoxicity against triple negative breast cancer (TNBC) cells. Tegafur 46-53 profilin 2 Homo sapiens 13-16 32838518-6 2020 Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Tegafur 132-139 thymidylate synthetase Homo sapiens 66-86 32838518-6 2020 Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Tegafur 132-139 profilin 2 Homo sapiens 173-176 32483952-9 2020 Palliative chemotherapy with tegafur, gimeracil, and oteracil (S-1) was restarted, and local pain was subsequently ameliorated. Tegafur 29-36 proteasome 26S subunit, non-ATPase 1 Homo sapiens 63-66 32793829-1 2020 S-1 is an anticancer agent that is comprised of tegafur, gimeracil, and oteracil potassium, and is widely used in various carcinomas including oral squamous cell carcinoma (OSCC). Tegafur 48-55 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 31011915-1 2019 BACKGROUND: S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 55-62 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 31011915-1 2019 BACKGROUND: S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 64-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 dihydropyrimidine dehydrogenase Homo sapiens 180-183 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 thymidylate synthetase Homo sapiens 230-250 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 thymidylate synthetase Homo sapiens 252-254 30734632-0 2019 Association between SLCO1B1 rs4149056 and tegafur-uracil-induced hepatic dysfunction in breast cancer. Tegafur 42-49 solute carrier organic anion transporter family member 1B1 Homo sapiens 20-27